Amendment to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing Of The Claims:

Claim 1 (Currently amended): A method for reducing symptoms of an immediate hypersensitivity reaction due to the presence of an amphiphilic carrier comprising administering a composition comprising a hypersensitivity reducing amount of a complement activation inhibitor, a therapeutic amount of an active ingredient(s) and an amphiphilic carrier to a subject having a condition responsive to the active ingredient(s), wherein said amphiphilic carrier is polyethoxylated oil or a derivatized polyethoxylated oil and is capable of causing an immediate hypersensitivity reaction in the subject, and wherein the active ingredient is taxol, paclitaxel, Doxil, althesin, cyclosporin, diazepham, didemnin E, echinomycin, propandid, steroids, teniposide, doxorubicin, daunorubicin, amphoterin B, hemoglobin, polynucleotide or a multivitamin and wherein the complement activation inhibitor is selected from sCR1, GS1, Indometacin, PAP, Zymosan, EGTA, Factor H, Factor I, C1qInh, complestatin, and anti-C5a, compound K-76COOH, diamines, small polyanions, sulfonated aromatic compounds, small synthetic peptide analogues of the C terminal part of C3, CAB-2, indel-proximal peptides, serine esterase inhibitors, antibodies specific for complement and anti-lipid antibodies.

Claim 2 (Previously presented): The method according to claim 1 wherein said composition further comprises a pharmaceutical solvent and emulsifiers or detergent.

Claim 3 (Previously presented): The method according to claim 2 wherein the pharmaceutical solvent is a hydrophilic or hydrophobic solvents.

Claim 4 (Previously presented): The method according to claim 1 wherein the polyethoxylated oil is polyethoxylated castor oil.

Claims 5 and 6 (Cancelled)

Claim 7 (Withdrawn): A pharmaceutical composition effective for inhibiting, treating, or reducing unwanted side effects caused by a drug composition including a drug and a solvent containing amphiphilic molecules in an individual, said pharmaceutical composition comprising a complement activation inhibitor in a pharmaceutically effective amount.

Claim 8 (Withdrawn): The pharmaceutical composition of claim 7 wherein said solvent contains polythoxylated oil.

Claim 9 (Withdrawn): The pharmaceutical composition of claim 7 wherein said complement activation inhibitor is selected from the group consisting of: sCR1, Factor H, Factor I, C1qInh, soluble forms of DAF, MCP, complestatin, and anti-C5a, compound K-76COOH, diamines, small polyanions, sulfonated aromatic compounds, small synthetic peptide analogues of the C terminal part of C3, CAB-2, indel-proximal peptides, serine esterase inhibitors, chimeric complement inhibitor proteins, and antibodies specific for complement proteins.

Claim 10 (Previously presented): The method of claim 1 wherein the administration includes: administering to said individual the complement activation inhibitor prior to the administration of said active ingredient.

Claim 11 (Withdrawn): An in vitro method for predicting hypersensitivity reactions in an individual resulting from a drug composition containing polyethoxylated oil, said method comprising incubating said drug composition with a sample of said individual's serum in vitro and detecting the presence or absence of complement activation.

Claims 12-15 (Canceled)

Claim 16 (Previously presented): The method according to claim 1 wherein said active ingredient is doxorubicin, daunorubicin or amphotericin B.

Claim 17 (Previously presented): The method according to claim 1 wherein the active agent is hemoglobin or polynucleotides.

Claim 18. (Withdrawn) A pharmaceutical composition effective for inhibiting, treating, or reducing unwanted side effects caused by a drug composition including a drug and a carrier containing amphiphilic molecules in an individual, said pharmaceutical composition comprising a complement activation inhibitor in a pharmaceutically effective amount.

Claim 19. (Withdrawn) The pharmaceutical composition of claim 18 wherein said complement activation inhibitor is selected from the group consisting of: sCR1, Factor H, Factor I, C1qInh, soluble forms of DAF, MCP, complestatin, and anti-C5a, compound K-76COOH, diamines, small polyanions, sulfonated aromatic compounds, small synthetic peptide analogues of the C terminal part of C3, CAB-2, indel-proximal peptides, serine esterase inhibitors, chimeric complement inhibitor proteins, and antibodies specific for complement proteins.

Claim 20. (Cancelled)

Claim 21. (Previously presented): The method according to claim 1 wherein the complement activation inhibitor is sCR1, GS1, Indometacin, PAP, Zymosan, EGTA and anti-lipid antibodies.

Claim 22 (Currently amended): In a method for treating a patient ~~involving~~ with a pharmaceutical composition containing a polyethoxylated or derivatized polyethoxylated oil-amphiphilic carrier and an active ingredient selected from paclitaxel, Doxil, althesin, cyclosporin, diazepham, didemnin E, echinomycin, propandid, steroids, teniposide, doxorubicin, daunorubicin, amphoterin B, hemoglobin, polynucleotide or a multivitamin wherein the improvement comprises a complement activation inhibitor present in the pharmaceutical composition in an amount sufficient to reduce symptoms of an immediate hypersensitivity reaction in the patient due to the presence of the amphiphilic carrier and where the complement activation inhibitor is selected from sCR1, GS1, Indometacin, PAP, Zymosan, EGTA, Factor H, Factor I, C1qInh, complestatin, and anti-C5a, compound K-76COOH, diamines, small polyanions, sulfonated aromatic compounds, small synthetic peptide analogues of the C terminal

part of C3, CAB-2, indel-proximal peptides, serine esterase inhibitors, antibodies specific for complement and anti-lipid antibodies.